Translate
Theravance Biopharma, Inc.
About
16.37USD+0.03 +0.18%
Closed • Updated at 13:18 GMT+00:00Market Cap$843.92M
P/E Ratio7.43
Volume277.6K
Beta1.27
RSI47.34
Gross Margin94.81%
Theravance Biopharma, Inc. — investor relations, events, news, and company updates on 6ix.
Latest News
May 7 2026
Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update
Mar 19 2026
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Mar 3 2026
Theravance Biopharma Reports Phase 3 CYPRESS Study Did Not Meet Primary Endpoint; Board Accelerates Strategic Review and Announces Cost Reduction Actions
Nov 20 2025
Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025
Nov 19 2025
Theravance Biopharma to Participate in Upcoming Investor Conferences
Recent Videos
Theravance Biopharma Inc. 2025 annual report
Mar 26, 2026
Theravance Biopharma Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development
Dec 10, 2025
Theravance Biopharma KOL Event
Dec 09, 2025
Theravance Biopharma, Inc TBPH Q3 2025 Earnings Call
Nov 18, 2025
Community Chat
Ask AI
Try asking